AsedaSciences®
Brad Calvin is a highly experienced professional who has held various key roles in the healthcare industry. Brad co-founded AsedaSciences and currently serves as the President and Co-Founder of the company. Throughout their career, Brad has been instrumental in defining strategic visions, leading marketing functions, and managing business units across multiple companies such as MaxCyte, Inc., GenMark Diagnostics, Beckman Coulter, and Abbott Diagnostics. With a background in B.Sc. Immunology, Microbiology, and Biochemistry from Curtin University, Brad has a strong foundation in the field.
This person is not in any teams
This person is not in any offices
AsedaSciences®
AsedaSciences was established with the vision of becoming a leader in optimized drug discovery through innovative cellular analysis. We provide multi-parametric, high content, high throughput phenotypic screening services to the pharmaceutical and bio-pharmaceutical industry for the assessment of compound toxicity or mechanism of action. Our unique platform utilizes the inherent strengths of flow cytometry, automated processes and sophisticated data analysis to deliver high value information that allows for earlier and more informed decisions during the drug discovery and development process. Innovative Cellular Analysis: Our systems-based approach to multi-parametric cellular analysis delivers high content, high value information on the biological effect of compounds on human cells to aid in compound classification early in drug discovery. Biological Fingerprints: We examine compound effects on integrated intra-cellular networks, targets and pathways to generate biological fingerprints that can be used for comparison to a database of known toxins and marketed therapeutics. Multiplexed Phenotypic Screens: We perform robust, high throughput, high content, multi-parametric phenotypic screens for the assessment of compound toxicity or mechanism of action. Our automated, operator independent analysis converts highly complex data into information for effective management of compound progression. Visit www.asedasciences.com for more details.